Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

S Miyamoto, N Miyake, LF Jarskog… - Molecular …, 2012 - nature.com
Since the introduction of chlorpromazine and throughout the development of the new-
generation antipsychotic drugs (APDs) beginning with clozapine, the D 2 receptor has been …

The serotonergic system and cognitive function

D Švob Štrac, N Pivac, D Mück-Šeler - Translational neuroscience, 2016 - degruyter.com
Symptoms of cognitive dysfunction like memory loss, poor concentration, impaired learning
and executive functions are characteristic features of both schizophrenia and Alzheimer's …

The serotonergic system in ageing and Alzheimer's disease

JJ Rodríguez, HN Noristani, A Verkhratsky - Progress in neurobiology, 2012 - Elsevier
Alzheimer's disease (AD) is one of the major neurodegenerative diseases that deteriorates
cognitive functions and primarily affects associated brain regions involved in learning and …

Serotonin and emotion, learning and memory

A Meneses, G Liy-Salmeron - Reviews in the Neurosciences, 2012 - degruyter.com
Abstract Serotonin (5-hydroxytryptamien, 5-HT) has been linked to emotional and
motivational aspects of human behavior, including anxiety, depression, impulsivity, etc …

Synthesis, Biological Evaluation, and Molecular Modeling of Donepezil and N-[(5-(Benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine Hybrids …

I Bolea, J Juarez-Jimenez, C de los Rı́os… - Journal of medicinal …, 2011 - ACS Publications
A new family of multitarget molecules able to interact with acetylcholinesterase (AChE) and
butyrylcholinesterase (BuChE), as well as with monoamino oxidase (MAO) A and B, has …

Activation of serotonin neurons promotes active persistence in a probabilistic foraging task

E Lottem, D Banerjee, P Vertechi, D Sarra… - Nature …, 2018 - nature.com
Abstract The neuromodulator serotonin (5-HT) has been implicated in a variety of functions
that involve patience or impulse control. Many of these effects are consistent with a long …

The treatment of cognitive impairment in schizophrenia

DC Goff, M Hill, D Barch - Pharmacology Biochemistry and Behavior, 2011 - Elsevier
Cognitive deficits are major contributors to disability in schizophrenia. Many pharmacologic
targets have been identified for cognitive enhancing agents, including receptors involved in …

Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.

M Nakamura, M Ogasa, J Guarino… - Journal of Clinical …, 2009 - psychiatrist.com
Objective: Lurasidone is a novel psychotropic agent with high affinity for D2 and 5-HT2A
receptors, as well as for receptors implicated in the enhancement of cognition and mood and …

An update of safety of clinically used atypical antipsychotics

L Orsolini, C Tomasetti, A Valchera… - Expert opinion on …, 2016 - Taylor & Francis
ABSTRACT Introduction: The atypical antipsychotic (APs) drugs have become the most
widely used agents to treat a variety of psychoses because of their superiority with regard to …

Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer's …

J Joubert, GB Foka, BP Repsold, DW Oliver… - European journal of …, 2017 - Elsevier
A series of 7-substituted coumarin derivatives were designed and synthesised to display
ChE and MAO-B inhibitory activity. The compounds consisted out of a coumarin structure …